Eculizumab
- PDF / 169,514 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 63 Downloads / 142 Views
1 S
Eculizumab Cholelithiasis: 3 case reports
A review of 51 patients with paroxysmal nocturnal haemoglobinuria treated with eculizumab described three patients [ages and sexes not stated], who developed cholelithiasis during treatment with eculizumab. The patients, who had paroxysmal nocturnal haemoglobinuria, started receiving eculizumab [routes and dosages not stated]. Subsequently, the patients developed cholelithiasis, which was attributed to eculizumab [durations of treatments to reactions onsets not stated]. The patients were successfully treated with surgery. In one of the patients intraoperative course was complicated due to significant varices present around the gallbladder associated with cavernous transformation of the portal vein secondary to prior thrombotic complications of paroxysmal nocturnal haemoglobinuria. This patient had severe symptoms of cholelithiasis, including bacteraemia from a biliary source. Of the remaining two patients, one patient had developed biochemical evidence of pancreatitis shortly before the surgery, while another patient had required a cholecystostomy tube placement due to severe gallbladder wall inflammation several weeks prior to the operation. Araten DJ, et al. Symptomatic bilirubin gallstones in patients with PNH treated with eculizumab. Blood 134 (Suppl. 1): 13 Nov 2019. Available from: URL: http:// doi.org/10.1182/blood-2019-124571 [abstract]
0114-9954/20/1787-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
803447003
Reactions 18 Jan 2020 No. 1787
Data Loading...
